Drug Trial Radar · NCT02038036
Ruxolitinib Efficacy and Safety in Patients With HU Resistant or Intolerant Polycythemia Vera vs Best Available Therapy.
Last checked: Nov 20, 2026Latest source record: Jul 20, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
149
Actual
Start
Mar 25, 2014
Primary completion
Sep 29, 2015
Study completion Apr 7, 2020
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Jan 16, 2014
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study compared the efficacy and safety of ruxolitinib to Best Available Therapy (BAT) in patients with polycythemia vera (PV) who were hydroxyurea (HU) resistant or intolerant and did not have a palpable spleen.
Conditions
- Polycythemia Vera
Interventions
Best Available TherapyDrug
Best Available Therapy as selected by the investigator from: Hydroxyurea, Pegylated-Interferon (IFN/PEG-IFN), pipobroman, anagrelide, IMIDs, or observation. Participants randomized to BAT who did not respond by Week 28 were eligible to crossover and start treatment with ruxolitinib.
RuxolitinibDrug
Ruxolitinib was administered at a starting dose of 10 mg twice a day (bid). Dose was adjusted based on efficacy and safety parameters up to a maximum dose of 25 mg bid.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants Achieving Hematocrit (Hct) Control at Week 28Time frame: Week 28
Locations
48 sites in 12 countries. Site status is shown where the registry gives one.
Novartis Investigative Site
Herston, Queensland, Australia
Novartis Investigative Site
Antwerp, Belgium
Novartis Investigative Site
Leuven, Belgium
Novartis Investigative Site
Toronto, Ontario, Canada
Novartis Investigative Site
Bordeaux, France
Novartis Investigative Site
Brest, France
Novartis Investigative Site
Lille, France
Novartis Investigative Site
Nice, France
Novartis Investigative Site
Paris, France
Novartis Investigative Site
Toulouse, France
Novartis Investigative Site
Bayonne, Bayonne Cedex, France
Novartis Investigative Site
Augsburg, Germany
Novartis Investigative Site
Dresden, Germany
Novartis Investigative Site
Jena, Germany
Novartis Investigative Site
Leipzig, Germany
Novartis Investigative Site
Magdeburg, Germany
Novartis Investigative Site
Mainz, Germany
Novartis Investigative Site
Minden, Germany
Novartis Investigative Site
Ulm, Germany
Novartis Investigative Site
Mannheim, Baden-Wurttemberg, Germany
Novartis Investigative Site
Budapest, Hungary
Novartis Investigative Site
Debrecen, Hungary
Novartis Investigative Site
Kaposvár, Hungary
Novartis Investigative Site
Mumbai, Maharashtra, India
Novartis Investigative Site
Vellore, Tamil Nadu, India
Novartis Investigative Site
Nahariya, Israel
Novartis Investigative Site
Netanya, Israel
Novartis Investigative Site
Tel Aviv, Israel
Novartis Investigative Site
Bologna, BO, Italy
Novartis Investigative Site
Florence, FI, Italy
Novartis Investigative Site
Rome, Lazio, Italy
Novartis Investigative Site
Milan, MI, Italy
Novartis Investigative Site
Pavia, PV, Italy
Novartis Investigative Site
Torino, TO, Italy
Novartis Investigative Site
Varese, VA, Italy
Novartis Investigative Site
Seoul, South Korea
Novartis Investigative Site
Seoul, South Korea
Novartis Investigative Site
Madrid, Spain
Novartis Investigative Site
Madrid, Spain
Novartis Investigative Site
Málaga, Andalusia, Spain
Showing 40 of 48 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.